Prestige Consumer’s ‘Nimble’ Marketing Helps Beat Fiscal 2021 Guidance

Less travel, closed schools and a slower cold/cough season during the pandemic required Prestige Consumer to invest strategically across its OTC healthcare portfolio in fiscal 2021. Dramamine motion sickness and Nix head lice treatments got less attention, while Monistat, Compound W and Clear Eyes received more.

4th quarter computer key on key board

Prestige Consumer Healthcare Inc.’s fiscal 2021, ended on 31 March, benefited from the company’s strategic focus during the pandemic on health conditions that consumers may be more inclined than ever to treat at home without a doctor’s visit.

“Share performance for a broad portfolio had an outstanding fiscal ’21, especially considering rapidly shifting consumer habits due to COVID,” said president and CEO Ron Lombardi in a 6 May call discussing the

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on HBW Insight for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from United States

More from North America